Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase

Journal of Lipid Research

Volumn 51, Issue 7, 2010, Pages 1801-1809

  Plihtari, Riia ^a   Hurt Camejo, Eva ^b   Öörni, Katariina ^a   Kovanen, Petri T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Atherosclerosis; Lowdensity lipoprotein; Proteolytic enzymes

Indexed keywords

CATHEPSIN S; CHYMASE; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2 GROUP V; PROTEOGLYCAN; SPHINGOMYELIN PHOSPHODIESTERASE; CATHEPSIN; PLASMIN;

AORTA; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; HUMAN TISSUE; LIPOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; PROTEIN ISOLATION; SENSITIZATION; HYDROLYSIS; METABOLISM; PARTICLE SIZE;

AORTA; CATHEPSINS; CHYMASES; FIBRINOLYSIN; GROUP V PHOSPHOLIPASES A2; HUMANS; HYDROLYSIS; LIPOLYSIS; LIPOPROTEINS, LDL; PARTICLE SIZE; PROTEOGLYCANS; SPHINGOMYELIN PHOSPHODIESTERASE;

EID: 77953491246     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M003103     Document Type: Article

References (39)

1. Williams, K. J., and I. Tabas. 1995. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15: 551-561.
2. Öörni, K., M. O. Pentikäinen, M. Ala-Korpela, and P. T. Kovanen. 2000. Aggregation, fusion, and vesicle formation of modied low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J. Lipid Res. 41: 1703-1714.
3. Kruth, H. S., and B. Shekhonin. 1994. Evidence for loss of apo B from LDL in human atherosclerotic lesions: extracellular cholesteryl ester lipid particles lacking apo B. Atherosclerosis. 105: 227-234.
4. Piha, M., L. Lindstedt, and P. T. Kovanen. 1995. Fusion of proteolyzed low-density lipoprotein in the fluid phase: a novel mechanism generating atherogenic lipoprotein particles. Biochemistry. 34: 10120-10129.
5. Dollery, C. M., and P. Libby. 2006. Atherosclerosis and proteinase activation. Cardiovasc. Res. 69: 625-635.
6. Mäyränpää, M. I., H. M. Heikkilä, K. A. Lindstedt, A. F. Walls, and P. T. Kovanen. 2006. Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion. Coron. Artery Dis. 17: 611-621.
7. Sukhova, G. K., G. P. Shi, D. I. Simon, H. A. Chapman, and P. Libby. 1998. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102: 576-583.
8. Hakala, J. K., R. Oksjoki, P. Laine, H. Du, G. A. Grabowski, P. T. Kovanen, and M. O. Pentikäinen. 2003. Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 23: 1430-1436.
9. Öörni, K., M. Sneck, D. Brömme, M. O. Pentikäinen, K. A. Lindstedt, M. Mäyränpää, H. Aitio, and P. T. Kovanen. 2004. Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modies low density lipoprotein particles in vitro. J. Biol. Chem. 279: 34776-34784.
10. Tabas, I., K. J. Williams, and J. Boren. 2007. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 116: 1832-1844.
11. Menschikowski, M., M. Kasper, P. Lattke, A. Schiering, S. Schiefer, H. Stockinger, and W. Jaross. 1995. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis. 118: 173-181.
12. Hurt-Camejo, E., S. Andersen, R. Standal, B. Rosengren, P. Sartipy, E. Stadberg, and B. Johansen. 1997. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17: 300-309.
13. Romano, M., E. Romano, S. Bjorkerud, and E. Hurt-Camejo. 1998. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler. Thromb. Vasc. Biol. 18: 519-525.
14. Wooton-Kee, C. R., B. B. Boyanovsky, M. S. Nasser, W. J. de Villiers, and N. R. Webb. 2004. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler. Thromb. Vasc. Biol. 24: 762-767.
15. Hanasaki, K., K. Yamada, S. Yamamoto, Y. Ishimoto, A. Saiga, T. Ono, M. Ikeda, M. Notoya, S. Kamitani, and H. Arita. 2002. Potent modication of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J. Biol. Chem. 277: 29116-29124.
16. Karabina, S. A., I. Brocheriou, G. Le Naour, M. Agrapart, H. Durand, M. Gelb, G. Lambeau, and E. Ninio. 2006. Atherogenic properties of LDL particles modied by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J. 20: 2547-2549.
17. Marathe, S., G. Kuriakose, K. J. Williams, and I. Tabas. 1999. Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specic components of the subendothelial extracellular matrix. Arterioscler. Thromb. Vasc. Biol. 19: 2648-2658.
18. Schissel, S. L., X. Jiang, J. Tweedie-Hardman, T. Jeong, E. H. Camejo, J. Najib, J. H. Rapp, K. J. Williams, and I. Tabas. 1998. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273: 2738-2746.
19. Xu, X. X., and I. Tabas. 1991. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J. Biol. Chem. 266: 24849-24858.
20. Schissel, S. L., J. Tweedie-Hardman, J. H. Rapp, G. Graham, K. J. Williams, and I. Tabas. 1996. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest. 98: 1455-1464.
21. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
22. Radding, C. M., and D. Steinberg. 1960. Studies on the synthesis and secretion of serum lipoproteins by rat liver slices. J. Clin. Invest. 39: 1560-1569.
23. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
24. Bolton, A. E., and W. M. Hunter. 1973. The labelling of proteins to high specic radioactivities by conjugation to a 125I-containing acylating agent. Biochem. J. 133: 529-539.
25. Rosengren, B., H. Peilot, M. Umaerus, A. C. Jonsson-Rylander, L. Mattsson-Hulten, C. Hallberg, P. Cronet, M. Rodriguez-Lee, and E. Hurt-Camejo. 2006. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler. Thromb. Vasc. Biol. 26: 1579-1585.
26. Hessler, J. R., D. W. Morel, L. J. Lewis, and G. M. Chisolm. 1983. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis. 3: 215-222.
27. Hurt-Camejo, E., G. Camejo, B. Rosengren, F. Lopez, O. Wiklund, and G. Bondjers. 1990. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J. Lipid Res. 31: 1387-1398. (Pubitemid 20261903)
28. Öörni, K., M. O. Pentikäinen, A. Annila, and P. T. Kovanen. 1997. Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modication of the lysine residues. J. Biol. Chem. 272: 21303-21311.
29. Bartold, P. M., and R. C. Page. 1985. A microdetermination method for assaying glycosaminoglycans and proteoglycans. Anal. Biochem. 150: 320-324.
30. Sneck, M., P. T. Kovanen, and K. Oorni. 2005. Decrease in pH strongly enhances binding of native, proteolyzed, lipolyzed, and oxidized low density lipoprotein particles to human aortic proteoglycans. J. Biol. Chem. 280: 37449-37454.
31. Hevonoja, T., M. O. Pentikäinen, M. T. Hyvönen, P. T. Kovanen, and M. Ala-Korpela. 2000. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modied LDL. Biochim. Biophys. Acta. 1488: 189-210.
32. Goni, F. M., and A. Alonso. 2002. Sphingomyelinases: enzymology and membrane activity. FEBS Lett. 531: 38-46.
33. Winget, J. M., Y. H. Pan, and B. J. Bahnson. 2006. The interfacial binding surface of phospholipase A2s. Biochim. Biophys. Acta. 1761: 1260-1269.
34. Linke, T., G. Wilkening, S. Lansmann, H. Moczall, O. Bartelsen, J. Weisgerber, and K. Sandhoff. 2001. Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins. Biol. Chem. 382: 283-290.
35. Skålen, K., M. Gustafsson, E. K. Rydberg, L. M. Hulten, O. Wiklund, T. L. Innerarity, and J. Boren. 2002. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 417: 750-754.
36. Paananen, K., and P. T. Kovanen. 1994. Proteolysis and fusion of low density lipoprotein particles independently strengthen their binding to exocytosed mast cell granules. J. Biol. Chem. 269: 2023-2031.
37. Hoff, H. F., C. L. Heideman, J. W. Gaubatz, D. W. Scott, J. L. Titus, and A. M. Gotto, Jr. 1978. Correlation of apolipoprotein B retention with the structure of atherosclerotic plaques from human aortas. Lab. Invest. 38: 560-567.
38. Smith, E. B. 1977. Molecular interactions in human atherosclerotic plaques. Am. J. Pathol. 86: 665-674.
39. Camejo, G., E. Hurt, and M. Romano. 1985. Properties of lipoprotein complexes isolated by afnity chromatography from human aorta. Biomed. Biochim. Acta. 44: 389-401.